New research indicates that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who halt conventional lifestyle plans.
Research printed in a major medical journal demonstrates that while obese people frequently drop substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing these treatments should be informed of the risk of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of regain means a reversion to original mass within about one and a half years.
Comparing Therapies
The study, which looked at 37 of trials involving thousands of participants, compared the results of these new drugs with older methods.
Scientists point out that people who lose weight through lifestyle changes alone generally have a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Regain
Doctors believe the mechanism of the drugs is key to understanding the heightened regain.
These medications mimic a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of GLP-1 levels several times higher than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement means appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Issue?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals contend that, given the significant potential of weight regain, the therapy is often life-long.
This view is supported by drug manufacturers, who state that the findings "highlight the long-term character of obesity," akin to managing conditions like hypertension.
User Testimonies
Users who have stopped the jabs report a powerful return of appetite.
"It felt as if a trigger that goes on and you become ravenous," described an individual.
The struggle is exacerbated if users have not developed sustainable dietary or behavioural modifications during therapy.
Significant Use
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is higher among females than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a magic fix and long-term success relies on ongoing behavioural changes.
